FDA-Approved Filler Juvèderm Volbella XC Now Available
Allergan has announced the availability of Juvèderm Volbella XC for lip augmentation and for correction of perioral rhytids in adults over the age of 21.
Juvèderm Volbella XC, a gel that combines different molecular weights of hyaluronic acid, was approved by the Food and Drug Administration in June. Clinical trial results showed the gel effectively increased lip fullness and softened the appearance of lines around the mouth associated with perioral rhytids in the majority of individuals through one year. Juvèderm Volbella XC is formulated with Vycross, a proprietary filler technology from Allergan. It is the only filler proven to last through one year in both the lips and perioral rhytids with optimal treatment.
The most common side effects observed in clinical trials were temporary responses at the treatment site such as swelling, tenderness, bruising, firmness lumps/bumps, redness, pain, discoloration, itching and dryness.
Physicians can purchase Juvèderm Volbella XC by completing an online training program (VolbellaTraining.com).
For more information visit Juvederm.com.